ArticleScience translational medicine2023
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Pooled it
- From mechanism to clinical: research evolution and hotspot analysis of CD276/B7-H3 in cancer immunotherapy.Frontiers in immunology · 2026Pooled it
- Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.Cancer discovery · 2026Article
- Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.Oncogene · 2026Article
- Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy.Nature communications · 2026Article
- B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Prostate Cancer at the Microbial Crossroads: Illuminating a New Frontier in Precision Medicine.The world journal of men's health · 2026Review
- Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation.Molecular cancer · 2026Review
- An Implantable Scaffold Sequentially Releasing STING Agonist and B7-H3 Antibody for Bone Metastasis Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting conserved domains of hypoxia-inducible factors for cancer therapy.The Journal of experimental medicine · 2026Article
- Prognostic and therapeutic roles of B7-H3 and B7-H4 in prostate cancer.Discover oncology · 2026Review
- Therapy-induced senescent cancer cells as bidirectional regulators of antitumor immunity and resistance in the tumor microenvironment.Cell death & disease · 2026Review
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
- Integrated scRNA-seq and bulk transcriptomics identify an amino acid metabolism-associated prognostic signature and highlight FUS as a potential driver in prostate cancer progression.Functional & integrative genomics · 2026Article
- Low-affinity binding of anti-B7-H3 clone MJ18 to murine B7-H3 fails to induce tumor regression.Scientific reports · 2026Article
- Palmitic acid-triggered B7H3 palmitoylation promotes immune escape.Nature communications · 2026Article
- Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.Cancer cell international · 2026Article
- B7-H3-mediated immune regulation in cancer: biological functions and therapeutic opportunities.Frontiers in pharmacology · 2026Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Wei ShiDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2236-4708
Yin WangDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4161-1353
Yuehui ZhaoDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Justin Jimin KimDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Haoyan LiDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6786-0705
Chenling MengDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Feiyu ChenDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jie ZhangDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Duncan H MakDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Vivien VanDepartment of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Javier LeoDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Brad St CroixTumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0002-6246-0374
Ana AparicioDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0900-0923
Di ZhaoDepartment of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6253-7127
The University of Texas MD Anderson Cancer Center · USFrederick National Laboratory for Cancer Research · US
Funding
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4MUsing mouse knockouts to unravel endothelial gene functionZIABC010736 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ST CROIX, BRADLEY D · 2009 to 2025
$4.4MDetermine the Role of Histone Methyltransferase ASH1L in Metastatic Prostate CancerR01CA278889 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Di Zhao · 2024 to 2026
$2.7MNovel Approaches Targeting B7-H3 in Castration-resistant Prostate CancerR01CA275990 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Di Zhao · 2023 to 2026
$2.3MNovel Therapeutic Approaches Targeting Tumor Suppressor Deficiencies in Advanced Prostate CancerR00CA226360 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHAO, DI · 2019 to 2021
$746kNCI NIH HHS P50 CA140388NCI NIH HHS R00 CA226360NCI NIH HHS R01 CA275990NCI NIH HHS R01 CA278889
Abstract
Checkpoint immunotherapy has yielded meaningful responses across many cancers but has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/
Indexed as
Prostatic NeoplasmsAnimalsB7 AntigensCell Line, TumorCTLA-4 AntigenDisease ProgressionHumansMaleMicePTEN PhosphohydrolaseSp1 Transcription FactorTumor Suppressor Protein p53Up-RegulationB7 AntigensCd276 protein, mouseCTLA-4 AntigenCtla4 protein, mousePTEN PhosphohydrolasePten protein, mouseSp1 Transcription FactorTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.